Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fed Conditions

This study has been completed.
Information provided by:
Teva Pharmaceuticals USA Identifier:
First received: February 6, 2009
Last updated: July 8, 2009
Last verified: July 2009
The purpose of this study is to assess the bioequivalence between Amoxicillin/Clavulanate Potassium Oral Suspension 600/42.9 mg/5 mL and Augmentin ES-600 Oral Suspension, 600/42.9 mg/5 mL in healthy, male and female subjects, under fed conditions.

Condition Intervention Phase
Drug: 600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL
Drug: Augmentin ES-600™
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
Official Title: An Open-Label, Single-Dose, Two-Way Crossover Bioequivalence Study of Two Oral Suspension Formulations of Amoxicillin/Clavulanate Potassium, 600/42.9 mg/5 mL in Healthy Subjects, Under Fed Conditions

Resource links provided by NLM:

Further study details as provided by Teva Pharmaceuticals USA:

Primary Outcome Measures:
  • Bioequivalence Based on Cmax for Amoxicillin [ Time Frame: Blood samples collected over 14 hour period ]
  • Bioequivalence Based on AUC0-Inf for Amoxicillin [ Time Frame: Blood samples collected over 14 hour period ]
  • Bioequivalence Based on AUC0-t for Amoxicillin [ Time Frame: Blood samples collected over 14 hour period ]
  • Bioequivalence Based on Cmax for Clavulanic Acid [ Time Frame: Blood samples collected over 14 hour period ]
  • Bioequivalence Based on AUC0-Inf for Clavulanic Acid [ Time Frame: Blood samples collected over 14 hour period ]
  • Bioequivalence Based on AUC0-t for Clavulanic Acid [ Time Frame: Blood samples collected over 14 hour period ]

Enrollment: 48
Study Start Date: August 2002
Study Completion Date: August 2002
Primary Completion Date: August 2002 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: 600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL
1 x 600 mg/42.9 mg/5 mL, single-dose fasting
Active Comparator: 2 Drug: Augmentin ES-600™
1 x 600 mg/42.9 mg/5 mL, single-dose fasting

Detailed Description:

Criteria for Evaluation: FDA Bioequivalence Criteria

Statistical Methods: FDA bioequivalence statistical methods


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy, non-smoking male or non-pregnant, non-lactating female subjects, 18 years of age and over.
  • Body weight within ±15% of the appropriate weight range published in 1993 by Metropolitan Life Insurance Company, Statistical Bureau and body-mass index (BMI) less than 30.
  • Negative for:

    • HIV
    • Hepatitis B and C
    • Urine drugs of abuse test (marijuana, amphetamines, barbiturates, cocaine, opiates, benzodiazepines and methadone).
    • Cotinine (urine test)
    • Breath alcohol (Breathalyzer)
    • HCG (females only)
  • No significant diseases or clinically significant abnormal laboratory values.
  • No clinically significant findings in the physical examination.
  • No clinically significant findings in vital sign measurements and 12-lead electrocardiogram (ECG).
  • Informed of the nature of the study and give written consent prior to receiving any study medication.
  • Female subjects: surgically steril, post-menopausal or practicing a recognized safe method of contraception (abstention, oral or implanted contraceptives, intra-uterine device or consistent condom plus spermicide use).

Exclusion Criteria:

  • Known history or presence of any disease or condition which might compromise the following body systems: immunologic, endocrine, renal, cardiovascular, respiratory, hematologic, gastrointestinal, neurologic, hepatic, psychiatric or dermatologic
  • More specifically: history or presence of significant: sensitivity to multiple allergens, diarrhea, stomach or intestinal disease, mononucleosis, renal or hepatic dysfunction and asthma.
  • Known or suspected carcinoma.
  • Known history or presence of:

    • Hypersensitivity or idiosyncratic reaction to amoxicillin, clavulanic acid, penicillin, cephalosporins and/or any other β-lactamase inhibitors.
    • Clavulin-associated jaundice/hepatic dysfunction.
    • Alcoholism within last 12 months.
    • Drug dependence and/or substance abuse.
    • Use of tobacco or nicotine-containing products, within last 12 months.
  • On a special diet within 4 weeks prior to drug administration (i.e. a deliberate change in diet for any reason).
  • Participation in another clinical trial or received an investigational product in the previous 30 days prior to drug administration.
  • Donation up to 250 mK of blood in the previous 30 days, 251-500 mKL in the previous 45 days, 501-750 mL in the previous 60 days or above 750 mL in the previous 90 days prior to study start.
  • Requirement of any medication, (prescription and/or over-the-counter) or dietary supplements on a routine basis, with the exception of occasional use of acetaminophen and oral or implanted contraceptives.
  • Difficulty fasting or consuming the standard prescribed meals.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00840840

Canada, Ontario
Pharma Medica Research Inc.
Toronto, Ontario, Canada, M1R 5A3
Sponsors and Collaborators
Teva Pharmaceuticals USA
Principal Investigator: Xueyu (Eric) Chen, M.D., Ph.D. Pharma Medica Research
  More Information Identifier: NCT00840840     History of Changes
Other Study ID Numbers: 02-544
Study First Received: February 6, 2009
Results First Received: May 18, 2009
Last Updated: July 8, 2009

Keywords provided by Teva Pharmaceuticals USA:
Healthy Subjects

Additional relevant MeSH terms:
Clavulanic Acid
Amoxicillin-Potassium Clavulanate Combination
Clavulanic Acids
beta-Lactamase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Bacterial Agents
Anti-Infective Agents processed this record on May 25, 2017